Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

THN102 reduces sleepiness for Parkinsonís patients
June 2020
SHARING OPTIONS:

LYON, France—A Phase 2 trial of THN102 in Parkinson’s disease ended positively for Theranexus, with the drug candidate meeting its primary endpoint of significantly reducing excessive daily sleepiness in Parkinson’s disease patients. THN102 was tested against placebo at two dosage levels: THN102 200mg modafinil/2mg flecainide and THN102 200mg modafinil/18mg flecainide. Patients who received THN102-200/2 had an improvement of 3.9 points on the Epworth Sleepiness Scale compared to 2.4 points for placebo, and the number of patients no longer experiencing excessive daytime sleepiness for the duration of treatment was 27.5 percent for the THN102-200/2 group vs. 16.2 percent for the placebo group. In addition, tolerability was excellent, with no impact on other motor disorders or symptoms.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.